Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PDS Biotechnology: Q4 Earnings Snapshot AP - Mon Mar 30, 6:10AM CDT

PDS Biotechnology: Q4 Earnings Snapshot

PDSB : 1.0700 (+8.08%)
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement GlobeNewswire - Mon Mar 30, 6:00AM CDT

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON,...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results GlobeNewswire - Tue Mar 24, 3:05PM CDT

PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval GlobeNewswire - Fri Feb 20, 7:30AM CST

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI GlobeNewswire - Wed Jan 28, 7:45AM CST

NCI-Led Study Shows Median PFS of 9.6 Months  Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 GlobeNewswire - Thu Jan 22, 7:45AM CST

PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint GlobeNewswire - Fri Jan 9, 7:45AM CST

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 ...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan GlobeNewswire - Tue Dec 9, 2025

New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s ...

PDSB : 1.0700 (+8.08%)
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) GlobeNewswire - Tue Dec 2, 2025

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 1.0700 (+8.08%)
PDS Biotechnology: Q3 Earnings Snapshot AP - Thu Nov 13, 2025

PDS Biotechnology: Q3 Earnings Snapshot

PDSB : 1.0700 (+8.08%)

Barchart Exclusives

As Amazon Takes on Chipmakers, Should You Buy AMZN Stock Here? Barchart - 5 minutes ago
Amazon stock pushed higher as the company revealed plans of selling AI chips and announces $25 billion data center investment in Mississippi. Here’s why these updates warrant buying AMZN shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.